Marketing authorisation holders are advised to submit any type IB variations or groupings of type IBs and type IAs by 3rd December 2021 for a start of procedure in 2021
It provides an option to automatically perform nodule detection immediately after chest X-ray imaging
It launched the most advanced "DTAS" (Direct to Angio Suite) & State of the art ‘Neuro-Angio’ technology
Acute therapies continue to report strong growth compared to chronic ones.
In India, MSD has signed non-exclusive licensing agreements with eight pharma companies.
The Phase 3 study is designed to bridge data collected from the vaccine efficacy trial conducted in India to the U.S. population
This capability programme aims to upskill 5000 nurses across the country in the next year by converting the current modules into an e-learning one
It plans to double its network to 50 centres across India in the next three years
It is the first integrated digital PCR solution ideal for oncology, cell and gene therapy development
Subscribe To Our Newsletter & Stay Updated
